Treatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Yasumura, Eduardo Gallatti ^a   Stilhano, Roberta Sessa ^a   Samoto, Vívian Yochiko ^a   Matsumoto, Priscila Keiko ^a   de Carvalho, Leonardo Pinto ^a   Lapchik, Valderez Bastos Valero ^a   Han, Sang Won ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HYPOXIA RESPONSIVE VECTOR; PLASMID VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL HYPOXIA; CELL STRAIN C2C12; CELL STRAIN HEK293; CONTROLLED STUDY; EXPRESSION VECTOR; GASTROCNEMIUS MUSCLE; GENE ACTIVATION; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIMB DISEASE; LIMB ISCHEMIA; LIMB NECROSIS; MALE; MOUSE; MUSCLE FORCE; MUSCLE MASS; MYOBLAST; MYOFIBROSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; TISSUE LEVEL; TREATMENT DURATION; ANIMAL; ANOXIA; CELL LINE; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; HINDLIMB; ISCHEMIA; METABOLISM; PATHOLOGY; VASCULARIZATION;

MUS;

ANIMALS; ANOXIA; CELL LINE; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HINDLIMB; HUMANS; ISCHEMIA; MICE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858638547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033944     Document Type: Article

References (39)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, et al. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 (Suppl 1): S1-75.
2. Hammond HK, McKirnan MD, (2001) Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc Res 49: 561-567.
3. Gupta R, Tongers J, Losordo DW, (2009) Human studies of angiogenic gene therapy. Circ Res 105: 724-736.
4. Rissanen TT, Yla-Herttuala S, (2007) Current status of cardiovascular gene therapy. Mol Ther 15: 1233-1247.
5. Carmeliet P, Collen D, (2000) Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 902: 249-262; discussion 262-244.
6. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
7. Grosskreutz CL, Anand-Apte B, Duplaa C, Quinn TP, Terman BI, et al. (1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58: 128-136.
8. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343.
9. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, et al. (1995) Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 21: 324-315.
10. Becit N, Ceviz M, Kocak H, Yekeler I, Unlu Y, et al. (2001) The effect of vascular endothelial growth factor on angiogenesis: an experimental study. Eur J Vasc Endovasc Surg 22: 310-316.
11. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, et al. (1995) Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 147: 1649-1660.
12. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, et al. (1996) Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 227: 628-635.
13. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, et al. (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662-670.
14. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, et al. (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290.
15. van Weel V, Deckers MM, Grimbergen JM, van Leuven KJ, Lardenoye JH, et al. (2004) Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res95: 58-66.
16. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, et al. (2000) Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330.
17. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, et al. (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898-901.
18. Semenza GL, (1999) Perspectives on oxygen sensing. Cell 98: 281-284.
19. Semenza GL, (2004) Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 19: 176-182.
20. Calos MP, (2006) The phiC31 integrase system for gene therapy. Curr Gene Ther 6: 633-645.
21. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, et al. (2006) Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 357: 28-48.
22. Su H, Arakawa-Hoyt J, Kan YW, (2002) Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci U S A America 99: 9480-9485.
23. Sacramento CB, Moraes JZ, Denapolis PM, Han SW, (2010) Gene expression promoted by the SV40 DNA targeting sequence and the hypoxia-responsive element under normoxia and hypoxia. Braz J Med Biol Res 43: 722-727.
24. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
25. Yuan Y, Hilliard G, Ferguson T, Millhorn DE, (2003) Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 278: 15911-15916.
26. Sacramento CB, Cantagalli VD, Grings M, Carvalho LP, Baptista-Silva JC, et al. (2009) Granulocyte-macrophage colony-stimulating factor gene based therapy for acute limb ischemia in a mouse model. J Gene Med 11: 345-353.
27. Sacramento CB, da Silva FH, Nardi NB, Yasumura EG, Baptista-Silva JC, et al. (2010) Synergistic effect of vascular endothelial growth factor and granulocyte colony-stimulating factor double gene therapy in mouse limb ischemia. J Gene Med 12: 310-319.
28. Hourde C, Vignaud A, Beurdy I, Martelly I, Keller A, et al. (2006) Sustained peripheral arterial insufficiency durably impairs normal and regenerating skeletal muscle function. J Physiol Sci 56: 361-367.
29. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370-374.
30. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, et al. (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90: 966-973.
31. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, et al. (2004) Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113: 516-527.
32. Nugent MA, Edelman ER, (1992) Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. Biochemistry 31: 8876-8883.
33. Maciag T, Mehlman T, Friesel R, Schreiber AB, (1984) Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 225: 932-935.
34. McCaffrey TA, Falcone DJ, Du B, (1992) Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol 152: 430-440.
35. von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, et al. (2006) Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 20: 2657-2659.
36. Wittenberg BA, Wittenberg JB, (1989) Transport of oxygen in muscle. Annu Rev Physiol 51: 857-878.
37. Wang GL, Semenza GL, (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90: 4304-4308.
38. Ruan H, Su H, Hu L, Lamborn KR, Kan YW, et al. (2001) A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3: 255-263.
39. Goto T, Fukuyama N, Aki A, Kanabuchi K, Kimura K, et al. (2006) Search for appropriate experimental methods to create stable hind-limb ischemia in mouse. Tokai J Exp Clin Med 31: 128-132.